Palmitoylethanolamide induces microglia changes associated with increased migration and phagocytic activity: involvement of the CB2 receptor

F Guida, L Luongo, S Boccella, M E Giordano, R Romano, G Bellini, I Manzo, A Furiano, A Rizzo, R Imperatore, F A Iannotti, E D'Aniello, F Piscitelli, F Sca Rossi, L Cristino, V Di Marzo, V de Novellis, S Maione, F Guida, L Luongo, S Boccella, M E Giordano, R Romano, G Bellini, I Manzo, A Furiano, A Rizzo, R Imperatore, F A Iannotti, E D'Aniello, F Piscitelli, F Sca Rossi, L Cristino, V Di Marzo, V de Novellis, S Maione

Abstract

The endogenous fatty acid amide palmitoylethanolamide (PEA) has been shown to exert anti-inflammatory actions mainly through inhibition of the release of pro-inflammatory molecules from mast cells, monocytes and macrophages. Indirect activation of the endocannabinoid (eCB) system is among the several mechanisms of action that have been proposed to underlie the different effects of PEA in vivo. In this study, we used cultured rat microglia and human macrophages to evaluate whether PEA affects eCB signaling. PEA was found to increase CB2 mRNA and protein expression through peroxisome proliferator-activated receptor-α (PPAR-α) activation. This novel gene regulation mechanism was demonstrated through: (i) pharmacological PPAR-α manipulation, (ii) PPAR-α mRNA silencing, (iii) chromatin immunoprecipitation. Moreover, exposure to PEA induced morphological changes associated with a reactive microglial phenotype, including increased phagocytosis and migratory activity. Our findings suggest indirect regulation of microglial CB2R expression as a new possible mechanism underlying the effects of PEA. PEA can be explored as a useful tool for preventing/treating the symptoms associated with neuroinflammation in CNS disorders.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
PEA induces CB2R expression via PPAR-α activation. (A) Real-time PCR analyses of CB2m-RNA in cultured microglia following incubation with PEA (1, 10 and 100 nM for 24 hours), using 18S as a loading control. Data are shown as mean ± SD (n = 6–8). *P < 0.05 compared to vehicle-treated cells. One way ANOVA, post-hoc Tukey’s. (B) Representative western blot image and related quantification showing the expression of CB2R in microglial cell lysates following incubation with vehicle, PEA (100 nM), GW6471 (10 µM) + PEA, or GW6471 alone, using β-actin as a loading control. Data are shown as mean ± SD (n = 6–8). *P < 0.05 compared to vehicle-treated cells, °P < 0.05 compared to PEA-treated cells. One way ANOVA, post-hoc Tukey’s. (C) CB2R expression (red) in Iba-1 labeled microglia (green) following incubation with vehicle, PEA (100 nM), GW7647 (1 µM), IFNγ (300 U/ml). Scale bar = 25 μm. (D) PPAR-α expression (green) in microglia cells (red) following incubation with vehicle, PEA (100 nM), GW7647 (1 µM), IFNγ (300 U/ml). Scale bar = 25 μm. (E) Representative western blot image and related quantification showing the expression of CB2R in microglial cell lysates incubated for 24 hours with vehicle, PEA (100 nM), GW7647 (1 µM), IFNγ (300 U/ml), in presence of siRNA or non-targeting siRNA. Data are shown as mean ± SD (n = 6). *P < 0.05 compared to vehicle, °P < 0.05 compared to relative control within non-targeting siRNA group. One way ANOVA, post-hoc Tukey’s. (E’) Real-time PCR analyses of PPAR-α/HPRT ratio in PPAR-α silencing (siRNA) or non-targeting siRNA conditions, compared with vehicle. Data are shown as means ± SD (n = 6). *P < 0.05, One way ANOVA, post-hoc Tukey’s. (F) Representative staining and related quantification of microglia cells in Iba-1 labeled microglia incubated for 24 hours with PEA (100 nM), GW7647 (1 µM) or IFNγ (300 U/ml), compared with vehicle-treated cells. Morphological evaluations measured as a percentage of activated cells over the total cell number. Data are shown as mean ± SEM (n = 6). ***Indicates statistically significant values (P < 0.0001) vs. vehicle-treated cells. One way ANOVA, post-hoc Tukey’s. Full-length gels are showed in Supplementary Figs S6 and S7.
Figure 2
Figure 2
Cnr2 is directly regulated by PEA-mediated PPAR-α activation: bioinformatic analysis and chromatin immunoprecipitation assay. (A) A schematic alignment of the human and rat Cnr2. The black boxes correspond to regions of high sequence homology between the two species contaning the putative PPARα/RXR sites indicated as small black rectangles in the lower part below the schematic. The PPARα/RXR matrix used for the analysis is also shown in the upper part. (B) Average data of the relative amount of the PPARα -immunoprecipitated DNA in HEK293 cells transfected with either control (pCDNA3) or murine PPARα and RXR encoding plasmids. Data are from three to six separate experiments and normalized relative to the input DNA, using the 2−ΔΔCt formula. The inset shows a representative agarose gel electrophoresis of the qPCR products obtained from PAX7-immunoprecipitated DNA for each experimental condition. Data are shown as mean ± SEM (n = 3) of three independent experiments conducted in triplicate. *p value ≤ 0.05 vscontrol condition (pcDNA-transfected cells), obtained using the unpaired T-TEST for statistical analyses.
Figure 3
Figure 3
PEA enhances phagocytosis and intracellular killing of P. gingivalis by microglial cells. Phagocytosis assay (A) and intracellular survival evaluation (B) were performed in the presence of PEA (100 nM), or GW6471 (10 µM) + PEA, or AM630 (100 nM) + PEA, or GW6471 alone. The number of bacteria ingested (at 90 min) or number of bacteria recovered (at 270 min) by the control group (vehicle) were considered to be 100%. Data are shown as means ± SEM (n = 6). *P < 0.05 compared to vehicle, °P < 0.05 compared to PEA. One way ANOVA, post-hoc Tukey’s.
Figure 4
Figure 4
PEA induces microglia migration towards a 2-AG source. (A) Image-based detection of 2-AG (100 µM) chemoattractive effect on cultured microglial cells after different treatments. Panel shows the migratory effect induced by PEA (100 nM) or GW7647 (1 µM), alone or in the presence of GW6471 (10 µM) or AM630 (100 nM), as compared to the control group (vehicle). Representative data of microglial cell time-lapse migration recorded at starting point (0 min), 30 and 90 min from the 2-AG exposure. (B) The quantification indicates the percentage of microglia cells affected by 2-AG chemoattractive movements vs total cell number at 90 min. Data are shown as means ± SEM (n = 6–8). *P < 0.05 compared to vehicle and °P < 0.05 compared to PEA or GW7647. One way ANOVA, post-hoc Tukey’s. Scale bar = 50 µm.

References

    1. Kettenmann H, Hanisch U-K, Noda M, Verkhratsky A. Physiology of microglia. Physiol. Rev. 2011;91:461–553. doi: 10.1152/physrev.00011.2010.
    1. McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64(1):46–54. doi: 10.1016/j.neuron.2009.09.033.
    1. Franco R, Fernàndez-Suàrezs D. Alternatively activated microglia and macrophages in the central nervous system. Prog. Neurobiol. 2015;131:65–86. doi: 10.1016/j.pneurobio.2015.05.003.
    1. Sierra A, Tremblay ME, Wake H. Never-resting microglia: physiological roles in the healthy brain and pathological implications. Front. Cell. Neurosci. 2014;8:240. doi: 10.3389/fncel.2014.00240.
    1. von Bernhardi R, von Bernhardi Eugenín L, Eugenín. Microglial cell dysregulation in brain aging and neurodegeneration. Front Aging Neurosci. 2015;7:124.
    1. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010;58(9):1017–1030. doi: 10.1002/glia.20983.
    1. Luongo L, et al. 1-(2′,4′-dichlorophenyl)−6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice. Neurobiol. Dis. 2010;37:177–185. doi: 10.1016/j.nbd.2009.09.021.
    1. Romero-Sandoval EA, Horvath R, Landry RP, DeLeo JA. Cannabinoid receptor type 2 activation induces a microglial anti-inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation. Mol Pain. 2009;28:5–25.
    1. Ehrhart J, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. Neuroinflammation. 2005;12(2):29. doi: 10.1186/1742-2094-2-29.
    1. Facci L, et al. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 1995;92:3376–3380. doi: 10.1073/pnas.92.8.3376.
    1. Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet. Dermatol. 2001;12(1):29–39. doi: 10.1046/j.1365-3164.2001.00214.x.
    1. Skaper SD, Facci L, Giusti P. Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator. Mol. Neurobiol. 2013;48(2):340–452. doi: 10.1007/s12035-013-8487-6.
    1. Mattace Raso G, Russo R, Calignano A, Meli R. Palmitoylethanolamide in CNS health and disease. Pharmacol. Res. 2014;86:32–41. doi: 10.1016/j.phrs.2014.05.006.
    1. Koch M, et al. Palmitoylethanolamide protects dentate gyrus granule cells via peroxisome proliferator-activated receptor-α. Neurotox Res. 2011;19(2):330–40. doi: 10.1007/s12640-010-9166-2.
    1. Costa B, Comelli F, Bettoni I, Colleoni M, Giagnoni G. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB(1), TRPV1 and PPARgamma receptors and neurotrophic factors. Pain. 2008;139:541–550. doi: 10.1016/j.pain.2008.06.003.
    1. Di Cesare Mannelli L, et al. Palmitoylethanolamide is a disease-modifying agent in peripheral neuropathy: pain relief and neuroprotection share a PPAR-alpha-mediated mechanism. Mediators Inflamm. 2013;2013:328797.
    1. Luongo L, et al. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets. 2013;12:45–54. doi: 10.2174/1871527311312010009.
    1. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J. 2006;8:298–306. doi: 10.1208/aapsj080234.
    1. Calignano A, La Rana G, Giuffrida A, Piomelli D. Control of pain initiation by endogenous cannabinoids. Nat. 1998;394:277–281. doi: 10.1038/28393.
    1. Calignano A, La Rana G, Loubet-Lescoulié P, Piomelli D. A role for the endogenous cannabinoid system in the peripheral control of pain initiation. Prog. Brain. Res. 2000;129:471–482. doi: 10.1016/S0079-6123(00)29034-1.
    1. LoVerme J, La Rana G, Russo R, Calignano A, Piomelli D. The search for the palmitoylethanolamide receptor. Life. Sci. 2005;77:1685–1698. doi: 10.1016/j.lfs.2005.05.012.
    1. Iannotti FA, Di Marzo V, Petrosino S. Endocannabinoids and endocannabinoid-related mediators: Targets, metabolism and role in neurological disorders. Prog. Lipid. Res. 2016;62:107–28. doi: 10.1016/j.plipres.2016.02.002.
    1. Cabral GA, Marciano-Cabral F. Cannabinoid receptors in microglia of the central nervous system: immune functional relevance. J. Leukoc. Biol. 2005;78(6):1192–1197. doi: 10.1189/jlb.0405216.
    1. Hains B, Waxman S. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J. Neurol. Sci. 2006;26:4308–4317.
    1. Chandra V, et al. Structure of the intact PPAR-gamma-RXR- nuclear receptor complex on DNA Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent. Nature. 2008;456(7220):350–6. doi: 10.1038/nature07413.
    1. Liu QR, et al. Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms,differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav. 2009;8(5):519–30. doi: 10.1111/j.1601-183X.2009.00498.x.
    1. Farquhar-Smith W-P, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology. 2003;99:1391–1401. doi: 10.1097/00000542-200312000-00024.
    1. Showalter V, Compton DR, Martin BR, Abood ME. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 1996;278(3):989–999.
    1. Re G, Barbero R, Miolo A, Di Marzo V. Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in companion animals. Vet. J. 2007;173(1):21–30. doi: 10.1016/j.tvjl.2005.10.003.
    1. Racz I, et al. Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J. Neurosci. 2008;28(46):12125–12135-a. doi: 10.1523/JNEUROSCI.3400-08.2008.
    1. Pasquini S, et al. Design, synthesis, and pharmacological characterization of indol-3-ylacetamides, indol-3-yloxoacetamides, and indol-3-ylcarboxamides: potent and selective CB2 cannabinoid receptor inverse agonists. J. Med. Chem. 2012;55(11):5391–402. doi: 10.1021/jm3003334.
    1. Mugnaini C, et al. Investigations on the 4-quinolone-3-carboxylic acid motif part 5: modulation of the physicochemical profile of a set of potent and selective cannabinoid-2 receptor ligands through a bioisosteric approach. Chem. Med. Chem. 2012;7(5):920–934. doi: 10.1002/cmdc.201100573.
    1. Luongo L, et al. 5′-Chloro-5′-deoxy-(±)-ENBA, a potent and selective adenosine A(1) receptor agonist, alleviates neuropathic pain in mice through functional glial and microglial changes without affecting motor or cardiovascular functions. Molecules. 2012;17:13712–26. doi: 10.3390/molecules171213712.
    1. Guida F, et al. Salvinorin A reduces mechanical allodynia and spinal neuronal hyperexcitability induced by peripheral formalin injection. Mol. Pain. 2012;8:60. doi: 10.1186/1744-8069-8-60.
    1. Guida F, et al. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol. Brain. 2015;8:47-a. doi: 10.1186/s13041-015-0139-5.
    1. Rinaldi B, et al. Effect of Prolonged Moderate Exercise on the Changes of Nonneuronal Cells in Early Myocardial Infarction. Neural Plast. 2015;2015:265967. doi: 10.1155/2015/265967.
    1. Spaziano, G. et al. Exposure to Allergen Causes Changes in NTS Neural Activities after Intratracheal Capsaicin Application, in Endocannabinoid Levels and in the Glia Morphology of NTS. Biomed. Res. 980983 (2015).
    1. Romero-Sandovalm EA, Horvathm RJ, De Leom JA. Neuroimmune interactions and pain: focus on glial-modulating targets. Curr. Opin. Investig. Drugs. 2008;9(7):726–734.
    1. Milliganm E, Watkins L. Pathological and protective roles of glia in chronic pain. Nat. Rev. Neurosci. 2009;10(1):23–36. doi: 10.1038/nrn2533.
    1. Lin YC, et al. Genome dynamics of the human embryonic kidney 293 lineage in response to cell biology manipulations. Nat. Commun. 2014;5:4767. doi: 10.1038/ncomms5767.
    1. Loria F, et al. Study of the regulation of the endocannabinoid system in a virus model of multiple sclerosis reveals a therapeutic effect of palmitoylethanolamide. Eur. J. Neurosci. 2008;28:633–41. doi: 10.1111/j.1460-9568.2008.06377.x.
    1. Ribes S, et al. Toll-like receptor stimulation enhances phagocytosis and intracellular killing of nonencapsulated and encapsulated Streptococcus pneumoniae by murine microglia. Infect. Immun. 2010;78(2):865–71. doi: 10.1128/IAI.01110-09.
    1. Nau R, Ribes S, Djukic M, Eiffert H. Strategies to increase the activity of microglia as efficient protectors of the brain against infections. Front. Cell. Neurosci. 2014;8:138. doi: 10.3389/fncel.2014.00138.
    1. Redlich S, Ribes S, Schutze S, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 by macrophages and increases the resistance of mice against infections. J. Neuroinflammation. 2014;11:108. doi: 10.1186/1742-2094-11-108.
    1. Masek K, Perlík F, Klíma J, Kahlich R. Prophylactic efficacy of N-2-hydroxyethyl palmitamide (impulsin) in acute respiratory tract infections. Eur. J. Clin. Pharmacol. 1974;7:415–9. doi: 10.1007/BF00560353.
    1. Redlich S, Ribes S, Scutze S, Czesnik D, Nau R. Palmitoylethanolamide stimulates phagocytosis of Escherichia coli K1 and Streptococcus pneumoniae R6 by microglial cells. J. Neuroimmunol. 2012;244(1–2):32–4. doi: 10.1016/j.jneuroim.2011.12.013.
    1. Singhrao, S. K., Harding, A., Poole, S., Kesavalu, L. & Crean, S. Porphyromonas gingivalis Periodontal Infection and Its Putative Links with Alzheimer’s Disease. Mediators Infiamm. 137357 (2015).
    1. Petrosino, S. & Di Marzo, V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. Br J Pharmacol. 13580 (2016).
    1. Kahlich R, et al. Studies on prophylactic efficacy of N-2-hydroxyethyl palmitamide (Impulsin) in acute respiratory infections. Serologically controlled field trials. J. Hyg. Epidemiol. Microbiol. Immunol. 1979;23:11–24.
    1. Inoue K. Microglial activation by purines and pyrimidines. Glia. 2002;40:156–163. doi: 10.1002/glia.10150.
    1. Miller AM, Stella N. CB2 receptor-mediated migration of immune cells: it can go either way. BR. J. Pharmacol. 2008;153(2):299–308. doi: 10.1038/sj.bjp.0707523.
    1. Thelen M. Dancing to the tune of chemokines. Nat. Immunol. 2001;2(2):129–134. doi: 10.1038/84224.
    1. Fung S, Cherry AE, Xu C, Stella N. Alkylindole-sensitive receptors modulate microglial cell migration and proliferation. Glia. 2015;63:1797–1808. doi: 10.1002/glia.22845.
    1. Franklin A, Parmentier-Batteur S, Walter L, Greenberg DA, Stella N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J Neurosci. 2003;23(21):7767–75.
    1. Walter L, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J. Neurosci. 2003;23(4):1398–405.
    1. Sacerdote P, et al. The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J. Neuroimmunol. 2005;159(1–2):97–105. doi: 10.1016/j.jneuroim.2004.10.003.
    1. Gonsiorek W, et al. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol Pharmacol. 2000;57(5):1045–50.
    1. Sugiura T, et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem. 2000;275(1):605–12. doi: 10.1074/jbc.275.1.605.
    1. Martin-Moreno AM, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. Mol. Pharmacol. 2011;79:964–973. doi: 10.1124/mol.111.071290.
    1. Di Marzo V, et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 2001;358:249–255. doi: 10.1042/bj3580249.
    1. Clark A, Wodarski R, Guida F, Sasso O, Malcangio M. Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia. 2010;58(14):1710–1726. doi: 10.1002/glia.21042.
    1. Luongo L, et al. The A1 adenosine receptor as a new player in microglia physiology. Glia. 2014;62:122–132. doi: 10.1002/glia.22592.
    1. Iannotti FA, Barrese V, Formisano L, Miceli F, Taglialatela M. Specification of skeletal muscle differentiation by repressor element-1 silencing transcription factor (REST)-regulated Kv7.4 potassium channels. Mol. Biol. Cell. 2013;24:274–84. doi: 10.1091/mbc.E11-12-1044.
    1. Matias I, Gonthier MP, Petrosino S, Docimo L, Capasso R, Hoareau L, Monteleone P, Roche R, Izzo AA, Di Marzo V. Role and regulation of acylethanolamides in energy balance: focus on adipocytes and beta-cells. Br J Pharmacol. 2007;152(5):676–90. doi: 10.1038/sj.bjp.0707424.
    1. Piscitelli F, Carta G, Bisogno T, Murru E, Cordeddu L, Berge K, Tandy S, Cohn JS, Griinari M, Banni S, Di Marzo V. Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab. 2011;8(1):51. doi: 10.1186/1743-7075-8-51.

Source: PubMed

3
S'abonner